Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo.
about
Emerging therapeutic delivery capabilities and challenges utilizing enzyme/protein packaged bacterial vesiclesKilling me softly--future challenges in apoptosis researchProtecting enzymatic function through directed packaging into bacterial outer membrane vesiclesRe-directing an alkylating agent to mitochondria alters drug target and cell death mechanismLipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Recent advances in antimultiple myeloma drug development.The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemiaSmall Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma.Utilisation of nanoparticle technology in cancer chemoresistance.Effects of DTX3L on the cell proliferation, adhesion, and drug resistance of multiple myeloma cells.ADP-ribosylation factor 1 (ARF1) takes part in cell proliferation and cell adhesion-mediated drug resistance (CAM-DR).Delivering a photosensitive transplatin prodrug to overcome cisplatin drug resistance.Cell adhesion down-regulates the expression of vacuolar protein sorting 4B (VPS4B) and contributes to drug resistance in multiple myeloma cells.Novel Approaches to Apoptosis-Inducing Therapies.Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma.Micellar nanoparticle formation via electrostatic interactions for delivering multinuclear platinum(II) drugs.Functionalized liposome purification via Liposome Extruder Purification (LEP).Extracellular vesicles as an efficient nanoplatform for the delivery of therapeutics.Radionuclides transform chemotherapeutics into phototherapeutics for precise treatment of disseminated cancer.Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.Nanotherapeutics for multiple myeloma.Germline mutations in lysine specific demethylase 1 (LSD1/KDM1A) confer susceptibility to multiple myeloma.
P2860
Q26801293-18C39FDD-0CC1-4981-8AF5-68285B63290CQ27025213-1B1EB2CC-87D7-4BE3-9479-C687BCC6E694Q27319739-7D8D0F5D-99E4-4BBE-A434-B7CF5F41623EQ28486104-5B5AEABA-3EFA-44E5-B7B3-29211C9ADE37Q30366990-2816D7D0-EFF2-4133-B4DE-76E118D05D19Q33416297-7A13CEE7-8A6A-4216-A245-D8743CC51369Q33655756-6EE3AF8E-7770-44B8-A280-13470AA53CF2Q35590573-DB7DE7E4-4842-4E50-9FCD-5DA6E8E079BDQ36421258-D0054652-A92B-4B09-9D20-2CF607B234B9Q38698894-5D6E4304-7854-464B-B11B-B8B8A342A62DQ38714809-3AEEB075-1BCB-4652-8967-EB875C79CC0FQ38861736-E6FAA008-3A00-4ED1-A164-A9F94F0FA46EQ38895636-B01677C9-DAD4-4400-B894-92847EDDB86EQ38936710-B7D46545-128B-4429-8CBD-81988E81EB12Q39139112-E40072C7-7A51-45B0-B0C2-CDF4770CE2B5Q39164469-EAE17EE9-54A9-437C-8EFE-6FA032CF2397Q46304429-C75F43BB-BB36-4530-9158-BC44D0999733Q47741822-D49876C6-EFF4-44DB-9582-A89E5EAC8340Q48215618-B542004A-983F-4CCB-965E-E7D769B1FD1DQ49358494-0CC22DA3-B184-4F1B-A5D7-A28543513A50Q52559684-7A143393-D943-4389-8983-FC6C73053C8AQ52646188-B1A6B4D2-1A76-458E-B378-A7810889372A
P2860
Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Rationally engineered nanopart ...... how enhanced efficacy in vivo.
@ast
Rationally engineered nanopart ...... how enhanced efficacy in vivo.
@en
type
label
Rationally engineered nanopart ...... how enhanced efficacy in vivo.
@ast
Rationally engineered nanopart ...... how enhanced efficacy in vivo.
@en
prefLabel
Rationally engineered nanopart ...... how enhanced efficacy in vivo.
@ast
Rationally engineered nanopart ...... how enhanced efficacy in vivo.
@en
P2093
P2860
P356
P1433
P1476
Rationally engineered nanopart ...... how enhanced efficacy in vivo.
@en
P2093
B Bilgicer
J D Ashley
J F Stefanick
M A Suckow
M W Handlogten
R M Navari
T Kiziltepe
P2860
P2888
P356
10.1038/BCJ.2012.10
P577
2012-04-20T00:00:00Z
P5875
P6179
1036877331